Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7046420
Reference Type
Journal Article
Title
Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study
Author(s)
Bourne, RRA; Kaarniranta, K; Lorenz, K; Traverso, CE; Vuorinen, J; Ropo, A; ,
Year
2019
Is Peer Reviewed?
1
Journal
BMJ Open
EISSN:
2044-6055
Publisher
BMJ PUBLISHING GROUP
Location
LONDON
Language
English
PMID
30944129
DOI
10.1136/bmjopen-2018-024129
Web of Science Id
WOS:000471157200042
Abstract
Bimatoprost-timolol (bimatoprost 0.03%-timolol 0.5% fixed-dose combination [FDC]) and tafluprost-timolol (tafluprost 0.0015%-timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost-timolol to PF tafluprost-timolol eye drops.
Tags
•
PFAS Universe
Data Source
Web of Science
Perflunafene
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity